NICE technology appraisal guidance
Issued: January 2007
TA116
Gemcitabine for the treatment of metastatic breast cancer
This is an extract from the guidance and may be misleading if read alone. The complete guidance is available at guidance.nice.org.uk/ta116
1 Guidance
1.1 Gemcitabine in combination with paclitaxel, within its licensed indication, is recommended as an option for the treatment of metastatic breast cancer only when docetaxel monotherapy or docetaxel plus capecitabine are also considered appropriate.